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Leber hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA (mtDNA)
disorder in the general population. It is an important cause of severe, usually irreversible, visual loss
among young adults with a peak age of onset in the second and third decades of life. Management is
currently mostly supportive but recent developments in LHON research are pointing the way towards
more effective treatments for this blinding mitochondrial disorder.
Copyright  2011, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Leber hereditary optic neuropathy (LHON, OMIM 535000) is
named after Theodore Leber (1840e1917), a German ophthalmol-
ogist who in 1871 ﬁrst described the deﬁning clinical features of
this disorder. LHON is the most common primary mitochondrial
DNA (mtDNA) disorder in the general population, with a minimum
prevalence of 1 in 31,000 in the North of England.1,2 Three mtDNA
point mutations, which all involve complex I subunits of the
mitochondrial respiratory chain, account for the vast majority of
LHON cases (Table 1).3,4 Other rarer mtDNA mutations have been
conﬁrmed as deﬁnitely causing the LHON phenotype, having been
reported in more than one pedigree and showing clear segregation
with affected disease status. For those putative LHON variants
identiﬁed in singleton cases or in single families only, additional
evidence is required before pathogenicity can be irrefutably
ascribed. The m.11778G>A mutation is found in over 70% of all
LHON patients, but as a result of a founder event, nearly 90% of
all affected carriers of French Canadian descent harbour the
m.14484T>C mutation.3,4 In most laboratories worldwide, the
diagnostic protocol for LHON involves a targeted molecular
approach, speciﬁcally looking for the three “primary” mtDNAne, Centre for Life, Newcastle
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e Ophthalmologic Society of Taiwamutations, i.e., m.3460G>A, m.11778G>A, and m.14484T>C. As full
mitochondrial genome sequencing still remains a time consuming
and expensive assay, it is only indicated if the initial LHON screen is
negative and there is a strong clinical suspicion.2. Clinical features of LHON
Telangiectatic vessels around the optic disc and ﬂuctuating
oedema of the retinal nerve ﬁbre layer (RNFL) can sometimes be
observed in asymptomatic LHON carriers. These oedematous areas
have been quantiﬁed with optical coherence tomography imaging
and RNFL thickening was found to be more prominent in the
temporal quadrant, in keeping with the greater vulnerability of the
papillomacular retinal ganglion cell (RGC) axons. With more
sophisticated psychophysical testing, other subclinical abnormali-
ties of optic nerve function have also been demonstrated, such as
reduced contrast sensitivity and depressed colour perception along
the red-green (protan) axis.3,4
LHON classically presents with acute or subacute painless loss of
central vision. The initial visual loss is severe with most patients
achieving best corrected visual acuities of 6/60 or worse.3,4 There is
an associated dense central scotoma and a marked reduction in
colour perception. Despite this global reduction in optic nerve
function, the pupillary light reﬂexes are relatively preserved, and
this distinctive feature has been ascribed to a special class of
melanopsin-containing RGCs that are less vulnerable to then. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Mitochondrial DNA variants associated with LHON
Mitochondrial
gene
Nucleotide change
Common
variants
(w90%)
MTND1 m.3460G>A*
MTND4 m.11778G>A*
MTND6 m.14484T>C*
Rare variants
(w10%)
MTND1 m.3376G>A, m.3635G>A*, m.3697G>A,
m.3700G>A, m.3733G>A*, m.4025C>T,
m.4160T>C, m.4171C>A*
MTND2 m.4640C>A, m.5244G>A
MTND3 m.10237T>C
MTND4 m.11696G>A, m.11253T>C
MTND4L m.10663T>C*
MTND5 m.12811T>C, m.12848C>T, m.13637A>G,
m.13730G>A
MTND6 m.14325T>C, m.14568C>T, m.14459G>A*,
m.14729G>A, m.14482C>A*, m.14482C>G*,
m.14495A>G*, m.14498C>T, m.14568C>T*,
m.14596A>T
MTATP6 m.9101T>C
MTCO3 m.9804G>A
MTCYB m.14831G>A
* These mtDNA variants are deﬁnitely pathogenic. They have been identiﬁed in
2 independent LHON pedigrees, showing segregation with affected disease status.
The remaining putative LHON mutations have been found in singleton cases or in
a single family, and additional evidence is required before pathogenicity can be
irrefutably ascribed.3,4
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eral optic nerve involvement at ﬁrst presentation occurs in
approximately 25% of acute LHON cases. If sequential, the second
eye is invariably affectedwithin one year of disease onset, unilateral
optic neuropathy being exceptionally rare in LHON.3,4
In the acute phase, optic disc hyperaemia, peripapillary telan-
giectatic vessels, vascular tortuosity, and retinal nerve ﬁbre layer
oedema can be observed, the latter being due to RGC axonal stasis
(Fig.1).3,4 In the pre-molecular era, these fundal abnormalities were
particularly informative, allowing a presumptive diagnosis of LHON
to bemade, especially when supported by amaternal family history
of early-onset visual loss. In 20e40% of acute cases, the optic discs
look entirely normal and these patients are often incorrectly
labelled as having functional visual loss.3,4 Pallor of the neuroretinal
rim develops within 6 weeks of disease onset and it is initially more
apparent temporally due to the accelerated loss of RGC axons
within the papillomacular bundle.
Extra-ocular features, such as cardiac conduction defects,
peripheral neuropathy, dystonia, and myopathy are thought toFig. 1. Fundal appearance in acute and chronic LHON stages. This 47-year-old m.11778G>A
months later. These fundal pictures were taken 1 month after the left eye had become involv
6/36 in the left eye. There is vascular tortuosity in both eyes and temporal pallor of the righ
within the papillomacular bundle, which sub-serves the central 10 of the visual ﬁeld. The
symptoms in that eye (acute stage). (L¼ left eye; R¼ right eye; T¼ temporal quadrant corrmore common among LHON carriers compared with the general
population.3,4 There is also a well-established association between
the three primary LHON mutations and a demyelinating illness,
which interestingly is clinically and radiologically indistinguishable
frommultiple sclerosis (Harding’s disease).6 Other rarer pathogenic
mtDNA variants have been linked with more atypical “LHON plus”
syndromes where the optic neuropathy is complicated by prom-
inent spastic dystonia, ataxia, juvenile-onset encephalopathy, and
psychiatric disturbances.3,4
3. Visual prognosis
The visual prognosis in LHON is poor and most patients remain
legally blind. The likelihood of visual recovery is greatest with the
m.14484T>C mutation, least with the m.11778G>A mutation, and
intermediate with the m.3460G>A mutation.3,4 Although delayed
visual recovery has been reported, maximal improvement in visual
function usually occurs within the ﬁrst year, if it occurs at all. The
appearance of small islands of vision within the patient’s visual
ﬁeld (fenestrations) can greatly help scanning vision, especially if
the central scotoma becomes concurrently less dense.
4. Genetic counselling
The mitochondrial genome is maternally inherited and thou-
sands of mtDNAmolecules are present in metabolically-active cells.
As a result of this high-copy number genome, two possible situa-
tions can arise, known as homoplasmy and heteroplasmy. Among
LHON families, 85e90% of carriers are homoplasmic for the mtDNA
mutation, i.e., 100% mutant, whereas the remainder are hetero-
plasmic harbouring a mixture of both wild-type and mutant
mtDNA species.2 The risk of disease conversion is low if the
mutational load is below the threshold level of 60%.7 Male LHON
carriers can be reassured that their children will not inherit their
mitochondrial genetic defect. However, female LHON carriers will
transmit the mutation to all their offspring. For the minority of
mothers with heteroplasmic LHON mutations, it is difﬁcult to
accurately predict the mutational level that will be transmitted
since rapid generational shifts in mitochondrial allele frequencies
can occur due to the “mitochondrial bottleneck” operating in the
female germline.8 Based on published ﬁgures, some indication of
recurrence risks can be provided to maternal relatives of a LHON
proband (Table 2).
Although it is not possible to predict whether or when a LHON
carrier will be affected, epidemiological studies have identiﬁedmale carrier experienced visual loss in his right eye ﬁrst, followed by his left eye 8
ed. Best corrected visual acuities at that point were counting ﬁngers in the right eye and
t optic disc (chronic stage) due to the earlier and more pronounced loss of RGC axons
re is mild hyperaemia of the left optic disc, in keeping with the recent onset of visual
esponding to the papillomacular bundle).
Table 2
Risk of visual loss for relatives of LHON probands
Risk of visual loss
m.11778G>A m.14484T>C
Siblings
Brother 25% 28%
Sister 8% 5%
Sister’s children
Nephew 41% 30%
Niece 7% 3%
Maternal ﬁrst cousins
Male 30% 19%
Female 7% 4%
The recurrence risks for the m.3460G>A mutation have not been determined in
a large number of pedigrees. However, these are unlikely to differ signiﬁcantly from
the reported estimates for the m.11778G>A and m.14484T>C LHON mutations.3,4
Fig. 2. Change in best visual acuity for patients with discordant visual acuities at
baseline. Catena is the formulation of idebenone provided by Santhera Pharmaceuti-
cals (Liestal, Switzerland). Patients randomised to the treatment arm received a total
dose of idebenone of 900 mg per day, with 300 mg taken three times a day during
meals. Of the 85 patients enrolled into the RHODOS trial, 30 had discordant visual
acuities at baseline, which was deﬁned as a difference of more than 0.2 LogMAR
between the two affected eyes.12 This degree of visual disparity is rare in late-stage
chronic LHON where patients usually have fairly symmetrical visual loss between
the two affected eyes. Patients with discordant visual acuities at baseline were
therefore at highest risk of further deterioration in the least affected eye, accounting
for the greater treatment effect observed in this particular subgroup. Log-
MAR¼ logarithm of the minimum angle of resolution.
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mental exposure.2e4 Over 90% of LHON carriers who will experi-
ence visual failure will do so before the age of 50 years. In addition,
LHON is characterised by a marked sex bias, male carriers having
approximately 50% lifetime risk of developing the optic neuropathy
compared with only approximately 10% for female carriers. Unaf-
fected LHON carriers should be strongly advised not to smoke and
to minimise their alcohol intake, not only as a general health
measure, but because smoking, and to a lesser extent excessive
alcohol intake, have been associated with increased risks of disease
conversion.3,4 In one large study comparing 196 affected and 206
unaffected carriers from 125 LHON families, light and heavy
smokers were twice and three times more likely to lose vision
compared to non-smokers, respectively.9
5. Treatment strategies
Mitochondria provide the bulk of the cell’s adenosine triphos-
phate (ATP) requirements through the tightly-regulated control
of electron ﬂux along the mitochondrial respiratory chain. All
three primary LHON mutations; m.3460G>A, m.11778G>A, and
m.14484T>C disrupt key polypeptide subunits of complex I,
resulting in a signiﬁcant bioenergetic deﬁcit and raised levels
of reactive oxygen species (ROS).10 An intriguing aspect of the
pathophysiology of LHON still remains e why are RGCs selectively
vulnerable to disturbed mitochondrial function? Several hypoth-
eses have been proposed based on the distinct anatomical, physi-
ological, and cytoskeletal arrangements present within the optic
nerve.10 Notwithstanding these unresolved issues, the ﬁnal path-
ological outcome in LHON is apoptotic RGC loss and the aims of
treatment for this disorder are three-fold: (1) to prevent initial
visual loss among LHON carriers; (2) to protect the unaffected
fellow eye in patients with unilateral optic neuropathy; and (3) to
preserve visual function in already compromised optic nerves.
5.1. Neuroprotection
Various treatment “cocktails” have been used to mitigate the
deleterious impact of mitochondrial dysfunction on RGC survival.3,4
Co-enzyme Q10 (CoQ10) is a quinone analogue and based on limited
evidence, it is frequently prescribed to patients with mitochondrial
disease. Idebenone is a related compound, a shorter-chain
synthetic benzoquinone analogue, which is thought to have
a better bioavailability proﬁle compared with CoQ10.11 Idebenone
is able to bypass complex I inhibition and by shuttling electrons
directly from the cytosol to complex III, ATP production is opti-
mised with a decrease in toxic ROS levels.11 This dual mode ofaction is an attractive therapeutic combination and anecdotally,
some patients with LHON have experienced signiﬁcant visual
recovery following treatment with idebenone.3,4 In collaboration
with clinical partners in the UK, Germany and Canada, we therefore
conducted a multicentre double-blind randomised controlled trial
(RCT) to investigate the safety, tolerability, and efﬁcacy of high-dose
idebenone in LHON. Rescue of Hereditary Optic Disease Outpatient
Study (RHODOS) successfully enrolled 85 patients harbouring
the three most common mtDNA LHON mutations: m.3460G>A
(n¼ 11), m.11778G>A (n¼ 57), and m.14484T>C (n¼ 17).12 These
patients were randomised in a 2:1 ratio to receive either high-dose
idebenone (900 mg) or placebo over a 24-week treatment period.
A major ﬁnding of the RHODOS trial is that patients with LHON
were more likely to beneﬁt from idebenone if they were treated
relatively early in the course of the disease (Fig. 2).12 The efﬁcacy of
idebenone has also been evaluated retrospectively in a cohort of
affected LHON carriers, all of whomwere older than 10 years of age
and within one year of disease onset.13 Follow-up clinical data were
collected for at least ﬁve years and visual outcome was compared
between patients who received idebenone (n¼ 44) against those
who were left untreated (n¼ 59). An increased frequency of visual
recovery was observed in the idebenone group and subgroup
analysis indicated that LHON carriers harbouring the m.11778G>A
mutation were the best responders. The early initiation of idebe-
none therapy in the acute phase of LHON was the most signiﬁcant
prognostic factor for visual improvement. No adverse drug reac-
tions were reported in both studies and idebenone is currently
under review by the European Medicines Agency for regulatory
approval.
Other neuroprotective agents are currently being investigated as
potential treatment options in LHON. In an open-label study of four
patients with acute LHON treated within 90 days of disease
conversion, the antioxidant a-tocotrienol-quinone (EPI-743),
a vitamin E derivative, has shown early promise and an RCT is
underway to study this compound further (http://www.aosonline.
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has yet to be established clinically, a marked amelioration in mito-
chondrial oxidative function was observed in cellular LHON models
following supplementation with oestrogen-based compounds.14
This protective effect provides a plausible explanation for the
reduced prevalence of visual loss among female LHON carriers and
the therapeutic potential of these oestrogen-based compounds
deserve further investigation.
5.2. Gene therapy
Gene therapy for primary mtDNA disorders is challenging. The
mitochondrial inner membrane is relatively impermeable and
a highly-efﬁcient vector is needed to transfect a sufﬁcient number
of mitochondria per cell in order to rescue the disease phenotype.
To circumvent these technical difﬁculties, a possible solution is the
so-called allotopic approach where the gene of interest is trans-
fected into the nuclear genome, and the encoded protein is engi-
neered with a speciﬁc targeting sequence that facilitates its uptake
into the mitochondrial compartment.10 RGC loss was dramatically
reduced, in both in vitro and in vivo experimental LHON models, by
transfecting themwith an adenovirus vector containing the human
SOD2 gene.15 In these conditions of heightened oxidative stress, the
over-expression of the antioxidant enzyme superoxide dismutase is
thought to promote RGC survival by exerting an anti-apoptotic
inﬂuence. Another attractive and more direct approach is to
replace the dysfunctional subunit encoded by the mtDNA LHON
mutation. Proof of this concept has recently been demonstrated in
a rat model harbouring a defective ND4 gene with the m.11778A>G
mutation.16 Visual loss was reversed by transfecting RGCs with the
wild-type version of the ND4 gene, the level of transgene expres-
sion being sufﬁcient to rescue RGCs and maintain normal physio-
logical responses.
6. Looking into the future
RHODOS is the ﬁrst RCT for a primary mitochondrial disorder
and the results obtained with high-dose idebenone are encour-
aging. A number of novel neuroprotective agents are currently in
the pipeline for other mitochondrial cytopathies and these could
also prove beneﬁcial for patients with LHON. Gene therapy is a valid
complementary approach to pharmacological intervention but
long-term safety data is essential before human clinical trials can be
advocated. After two decades of sustained research, we are now at
the start of an exciting translational phase, not only for LHON, but
for other mitochondrially-determined optic neuropathies, which as
a group represent an important cause of chronic visual morbidity in
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